Pfizer, BioNTech Rise After FDA Approves Covid Boosters for Children By

© Reuters

By Liz Moyer — Pfizer Inc (NYSE:) shares rose after the Food and Drug Administration approved its Covid-19 booster shot for children aged 5 to 11.

Pfizer stock rose 0.6% in mid-afternoon trading on Tuesday and BioNTech SE (NASDAQ:) shares rose 5.5%. Shares of their rival in mRNA vaccines against Covid, Moderna Inc (NASDAQ:), jumped 3.7%.

The FDA said that the data show the protection provided by two shots fades with time and that a third shot can shore up protection for children. It added that the benefits outweigh the risks.

Still, parents seem to be holding off on vaccinating this school-aged group. Less than 30% of children 5 to 11 have gotten their primary two doses as of April, according to the Centers for Disease Control and Prevention, which is expected to meet Thursday to sign off on the boosters as well.

The advisory committee on vaccines for the FDA plans to meet in June to review requests from Pfizer and Moderna to approve the Covid vaccines for children under age 5.

Source: Investopedia